JDRF is excited to be part of an international consortium of 23 public and private organizations that are aiming to better understand low blood sugar, called hypoglycemia, and its impact on people with type 1 diabetes (T1D). Hypoglycemia is a real fear for people with T1D. It can arise if one takes too much insulin. Most of the time, low blood sugar is caught early on, with symptoms such as sweating, fatigue, hunger and/or irritability. In that case, people can eat or drink a fast-acting carbohydrate—like juice or glucose tablets—to bring the blood sugar back to normal range. But, if it’s not caught early, it can cause people with T1D to have difficulty speaking, have seizures or become unconscious.
But much about hypoglycemia remains unknown. That’s why Hypo-RESOLVE (Hypoglycemia – REdefining SOLutions for better liVEs) aims to provide researchers and clinicians with a better classification of hypoglycemia by:
- Creating a database of 100 to 150 recently conducted clinical trials
- Conducting a series of statistical analyses to define predictors and consequences of hypoglycemia
- Calculating the financial cost of hypoglycemia
- Updating the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on findings emerging from Hypo-RESOLVE
The end result will provide a much needed resolution on hypoglycemia-related questions and should, ultimately, lead to better preventative measures and treatments for those living with T1D.
For more information, read the press release here.